DrJ:

You've hit the important points.  In particular, the 21 days - had it gone on longer, would there have been complete eradication?  Reduced the number of tumours by 68% - was not expecting any of that!  I was expecting tumour growth arrest with maybe some shrinkage, but this is indeed profound.  This in a nutshell is validation of the Transcend technology.  If there were lingering questions about whether Transcend altered the functionality of the underlying biologic, that would have been put to rest with this data.  It will be very interesting to see the reaction by Roche to this.  In my estimation, it will be impossible for them to ignore this type of data.

.

One would think that Abbott, UCB & MedImmune (and whom ever else is at the table) would be greatly encouraged by this NR because Transcend did not affect the underlying biologic and efficacious quantities were delivered (that would seem an understatement).  With respect to Shire, maybe some of the rumours that have been floating around about Shire not believing the results because they were much better than expected are indeed true. 

.

Congratulations are in order to Rob Hutchison, Wilf Jeffries, Reinhardt Gabathuler and the Bioasis team.  It's taken somewhat longer than most expected, but going the route of using well respected agencies on this program like the NRC, BC Cancer and TTU to carry out the programs and provide third party validation has been well worth it.   Don't forget, that Quentin Smith & Paul Lockman are well known by Roche and Quentin worked on the original Herceptin project back in the 1990's.  Perhaps they will have a 'renewed interest' in each other's work in the near future?

.

If your thinking is:  "Well, it's only mice - not humans", I would agree if we were dealing with a new biologic, but that is not the case with BT2111.  Mice brain physiology is closely related to that of humans and don't forget, we are using human p97 and the same receptors exist on the mice BBB as in humans.  In addition, species specific p97 trancytosis much better.  What route will this take with respect to the NIH?  Will this now be fastracked?  Don't forget, Quentin Smith worked for the NIH for ~10 years as well.

.

The days ahead, are days that an investor can not afford to be out of this stock.  This NR is a significant anchor into the next phase of Bioasis and a game changer.  It might take a few days for the pharma world to digest this, but this will definitely bring about a reaction.

.

Congratulations to all with the fortitude to 'hang in there'.